What's Trending in Stocks Right Now
Discover which stock market news stories are capturing the most attention today. This page shows you the most-viewed articles on StockTitan, updated every minute based on real visitor traffic. See what tens of thousands of traders and investors are reading right now.
Why this matters: When a news story suddenly gets massive readership, it often indicates significant market interest in that stock or sector. By tracking the most popular articles, you can quickly identify which companies and events are drawing investor attention and potentially moving markets.
This isn't editorial content or sponsored placement—it's based purely on reader activity. Every story below earned its position through actual page views from real visitors, making this an authentic snapshot of what the trading community finds most interesting. Whether it's earnings reports, FDA decisions, merger news, or market analysis, the most-read stories rise to the top.
Updated Every Minute: Market sentiment shifts quickly. This ranking is recalculated every 60 seconds to reflect the latest reading trends. What's trending now could be completely different in an hour as new stories break and capture attention.
Alterity Therapeutics (NASDAQ: ATHE) reported a successful End-of-Phase 2 meeting with the U.S. FDA for its MSA candidate ATH434, securing FDA alignment on the pivotal Phase 3 program design.
The FDA agreed on the study population, 50 mg twice-daily dosing, treatment duration, and primary endpoint UMSARS Part I, after Phase 2 data showed 48% slowing of disease progression versus placebo. Key secondary endpoints and statistical methods were also accepted, and the Phase 3 program is intended to support a potential NDA. ATH434 already holds Fast Track and Orphan Drug designations for MSA. Trial activities are planned to begin by year-end 2026.
- FDA alignment on key Phase 3 design elements for ATH434 in MSA
- UMSARS Part I accepted as Phase 3 primary endpoint
- 50 mg BID dose advanced after 48% slowing vs placebo in Phase 2
- Phase 3 program intended to support a potential NDA in MSA
- FDA acceptance of key secondary endpoints and statistical methods
- ATH434 holds Fast Track and Orphan Drug designations for MSA
- Phase 3 trial activities targeted to start by year-end 2026
- None.
SoundHound AI (Nasdaq:SOUN) will participate in the D.A. Davidson 2026 Technology & Consumer Conference on June 11, 2026, in Nashville, Tennessee.
CEO and Co-Founder Keyvan Mohajer will join a fireside chat at 12:20 PM PT, with a live webcast available via the company’s investor relations website.
- None.
- None.
Rivian (NASDAQ:RIVN) began first public customer deliveries of its all-new R2 mid-size electric SUV and opened ordering invitations for existing reservation holders. R2 is built on a new platform at Rivian’s Normal, Illinois plant, targeting a broader, more affordable EV market.
Initial deliveries focus on the R2 Performance with Launch Package, starting at $57,990 and offering up to 330 miles of EPA-estimated range, 0–60 mph in 3.6 seconds, dual-motor AWD, and a tow rating of 4,400 lbs.
- Start of public R2 deliveries and order invitations for reservation holders
- Initial R2 Performance with Launch Package priced from $57,990
- Future R2 trims planned from $53,990 down to $44,990
- EPA-estimated R2 range up to 330 miles with dual-motor AWD
- Autonomy+ platform priced at $49.99/month or $2,500 one-time
- Normal, Illinois plant and future Georgia facility targeting 300,000 units annual capacity
- None.
Aditxt (Nasdaq: ADTX) signed a definitive business combination agreement that values its 100%-owned subsidiary Ignite Proteomics at about $150 million. Ignite is expected to separate and list on the NYSE via a new holding company, while Aditxt remains a separate Nasdaq-listed health innovation company.
- Ignite Proteomics valued at approximately $150 million implied equity value
- Aditxt expected to unlock value from its 100%-owned Ignite subsidiary
- Ignite to gain independent NYSE-listed public-company platform
- Net proceeds expected to fund commercialization and clinical evidence generation
- Boards of all applicable parties have approved the business combination
- Ignite management expected to lead the combined public holding company
- Closing subject to multiple customary conditions and regulatory approvals
- Transaction dependent on acquisition corp shareholder and Ignite equity holder approvals
- Minimum cash and financing conditions must be satisfied before completion
QTREX Quantum (Nasdaq: QTEX) received an approximately $1 million grant from the Israel Innovation Authority to develop a native RF dielectric material for superconducting quantum computing connectivity.
The program focuses on high-density, low-loss RF signal routing inside cryogenic environments, targeting connectivity bottlenecks as quantum processors scale.
- Approximately $1 million Israel Innovation Authority grant secured for materials R&D
- Funding focused on native RF dielectric layer within QTREX quantum connectivity architecture
- Targets high-density, low-loss RF routing for superconducting quantum systems
- Supports engagement in technical and commercial discussions with quantum hardware companies
- None.
Incannex (Nasdaq: IXHL) announced that Alliance Global Partners has initiated equity research coverage with a BUY rating and a US$18.00 price target, in a report dated June 8, 2026 by analyst James Molloy.
The coverage evaluates Incannex’s clinical pipeline, including IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder, and is expected by the company to broaden investor awareness. AGP has received compensation from Incannex for investment banking services.
- None.
- None.
Global Mofy AI (Nasdaq:GMM) will implement a 1-for-50 reverse stock split of its class A and class B ordinary shares, effective for trading on June 11, 2026 under the same ticker. The action will reduce outstanding class A shares from about 89.58 million to 1.79 million and class B shares from about 8.17 million to 0.16 million. No fractional shares will be issued; holders otherwise entitled to fractions will receive one full share.
- None.
- None.
Mingteng International (Nasdaq: MTEN) priced a registered direct offering with certain institutional investors, selling up to 1,131,004 Class A ordinary shares and prefunded warrants at $2.00 per share.
The deal is expected to raise approximately $2.26 million in gross proceeds, mainly for working capital and general corporate purposes, and is expected to close around June 10, 2026, subject to customary conditions.
- Expected gross proceeds of about $2.26 million to fund operations
- Up to 1,131,004 new Class A ordinary shares and prefunded warrants sold
- Use of an effective Form F-3 shelf registration streamlines capital raising
- Exclusive placement agent FT Global Capital may help ensure transaction execution
- New shares and prefunded warrants may lead to shareholder dilution
- Net proceeds reduced by placement agent fees and offering expenses
Zscaler (NASDAQ: ZS) announced an expanded phase of Project AI-Guardian, uniting its Zero Trust Exchange with leading AI, cloud, and infrastructure partners to secure enterprise AI at scale.
New integrations provide AI access mapping, attack-surface modeling, governance, and real-time zero trust enforcement across enterprise AI workflows.
- None.
- None.